Despite an already strong run, Hua Medicine (Shanghai) Ltd. (HKG:2552) shares have been powering on, with a gain of 27% in the last thirty days. The last 30 days bring the annual gain to a very sharp 91%.
After such a large jump in price, given around half the companies in Hong Kong’s Pharmaceuticals industry have price-to-sales ratios (or “P/S”) below 1.5x, you may consider Hua Medicine (Shanghai) as a stock to avoid entirely with its 10x P/S ratio. However, the P/S might be quite high for a reason and it requires further investigation to determine if it’s justified.
View our latest analysis for Hua Medicine (Shanghai)
How Has Hua Medicine (Shanghai) Performed Recently?
With revenue growth that’s exceedingly strong of late, Hua Medicine (Shanghai)…
